



Ovantic
L I F E S C I E N C E S

ORPHAN DRUG INITIATIVE

Advancing Hope Through Science

Ovantic Life Sciences Inc.
Corporate Headquarters
5 Concourse Parkway
Sandy Springs, GA 30328

☎ 1-888-885-5933

📅 1-888-805-5526

🌐 www.ovantic.com

Ovantic Life Sciences Inc.
400 Renaissance Center, Suite 2600
Detroit, MI 48243



ORPHAN DRUG DEVELOPMENT

Ovantic Life Sciences has established a global initiative dedicated to the research, development, and manufacturing of Orphan Drugs, treatments for rare diseases that affect small patient populations but have a profound global impact.

Our programs are designed to bring innovative, accessible therapies to underserved communities, improving both quality of life and long-term health outcomes for individuals living with rare disorders.

Beyond medical impact, orphan drug development provides measurable economic and public health benefits. Effective treatments reduce long-term healthcare costs, hospitalizations, and patient dependency, while improving overall productivity and longevity.

PRODUCT PIPELINE

OXREXA™

**INNOVATIVE TREATMENT FOR
SICKLE CELL ANEMIA**




ABOUT SICKLE CELL ANEMIA

Sickle cell anemia is a rare, inherited blood disorder caused by a mutation in the HBB gene, which provides instructions for producing beta-globin, a key component of hemoglobin — the protein in red blood cells that carries oxygen throughout the body.

This genetic mutation leads to the formation of abnormal, sickle-shaped red blood cells that are rigid and prone to blocking small blood vessels. These blockages cause pain crises, anemia, organ damage, and increased risk of infection.

While current therapies — such as antibiotics, blood transfusions, and stem cell transplants — can manage symptoms, there remains an urgent global need for accessible and sustainable treatment solutions.

Ovantic Life Sciences is advancing Oxrexa™, an innovative therapy designed to improve accessibility and enhance the lives of individuals living with sickle cell disease across the world.



FUTURE FOCUS AREAS

Ovantic Life Sciences continues to expand its Orphan Drug Initiative across multiple rare diseases with strategic regional insights and research partnerships.

Disease	Most Prevalent Regions	Regional Insights / Strategic Focus
Amyotrophic Lateral Sclerosis (ALS)	North America, Western Europe, Japan, Australia	Higher prevalence in developed regions (2–3 cases per 100,000). Rising diagnoses in Asia-Pacific.
Duchenne Muscular Dystrophy (DMD)	North America, Europe, Middle East, Latin America	Global distribution; underdiagnosed in Africa and Asia. Gene therapy cost barriers create access opportunities.
Systemic Sclerosis (Scleroderma)	North America, Europe, India, East Asia	More common in women. Increasing prevalence in India and Japan; opportunity for anti-fibrotic innovations.
Pompe Disease	Europe, North America, China, Japan	Infantile form more frequent in Asia-Pacific. Enzyme therapies remain unaffordable in low-resource countries.
Beta Thalassemia	Mediterranean, Middle East, South Asia, Sub-Saharan Africa	Concentrated in developing regions; ~40 million carriers in India alone. Strong case for affordable therapeutics.
Cystic Fibrosis (CF)	North America, Western Europe, Australia	Historically prevalent in Caucasian populations; new cases rising in South Asia and the Middle East.
Friedreich's Ataxia (FRDA)	North America, Europe, Middle East	Genetic clusters in Europe and North America. Significant therapeutic gap in Latin America and Africa.
Retinitis Pigmentosa (RP)	Asia, Africa, Latin America, Europe	Affects ~2 million globally. Highest rates in North Africa and the Middle East. Antioxidant ophthalmic treatments emerging.
MELAS (Mitochondrial Encephalomyopathy)	Asia (Japan, China), Europe, North America	Mutation prevalence highest in Asia; need for global mitochondrial therapy access.
Fanconi Anemia	North America, Europe, India, Brazil, South Africa	Genetic clusters in India and South Africa. Poor transplant access drives need for novel therapies.




Ovantic
L I F E S C I E N C E S



GLOBAL VISION

Through its Orphan Drug Initiative, Ovantic Life Sciences is building a future where innovative, life-changing treatments for rare diseases are accessible, affordable, and globally distributed.

Our mission is to bridge the gap between scientific discovery and patient accessibility, focusing on diseases that impact millions but remain underserved.

 1-888-885-5933

 www.ovantic.com

 info@ovantic.com